Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$130.79

8.61 (7.05%)

08:16
10/15/18
10/15
08:16
10/15/18
08:16

Sarepta signs license agreement with Lysogene for LYS-SAF302

Sarepta announced it has signed a license agreement with Lysogene for the development of a gene therapy, LYS-SAF302, to treat Mucopolysaccharidosis type IIIA, or MPS IIIA. Under the terms of the agreement, Sarepta will also have certain option rights to an additional CNS-targeted gene therapy candidate. Under the terms of the license, Lysogene shall be responsible for completion of the pivotal trial, which is set to commence in Q4. Sarepta shall have exclusive commercial rights to LYS-SAF302 in the United States and all territories outside of Europe, and Lysogene will retain exclusive commercial rights to LYS-SAF302 in Europe. Sarepta will be responsible for global manufacturing of LYS-SAF302 and will supply Lysogene for its territory. Sarepta will make committed cash payments to Lysogene totaling $26M plus the purchase of Lysogene equity for $2.5M. In 2019, Sarepta will pay Lysogene up to an additional $19M. Payments from Sarepta to Lysogene for all items, if all milestones are met, would total approximately $125M plus royalties. The financial terms of the agreement significantly extend Lysogene's cash runway, enabling the company to continue the development of its other assets.

SRPT Sarepta
$130.79

8.61 (7.05%)

10/12/18
BERN
10/12/18
INITIATION
Target $170
BERN
Outperform
Sarepta initiated with an Outperform at Bernstein
Bernstein analyst Vincent Chen initiated Sarepta with an Outperform rating and $170 price target. In a research note to investors, Chen says that a "confluence" of factors make DMD a best case scenario, and very high value, for gene therapy, and while he says manufacturing is not easy, he does not think it will be a problem. Chen says he is "fairly" confident Sarepta can succeed after a deep dive into gene therapy manufacturing.
10/04/18
JANY
10/04/18
NO CHANGE
Target $200
JANY
Buy
Sarepta micro-dystrophin gene therapy update continues to impress, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong believes the three-month muscle biopsy data from the fourth patient and the functional results from all four patients that Sarepta reported at the Annual Congress of the World Muscle Society provide "strong" additional evidence to support a favorable clinical profile of the micro-dystrophin gene therapy program. The analyst notes that management has requested a meeting with the FDA and he continues to expect the agency to be supportive for an expedited regulatory pathway. Upon FDA feedback, patient dosing in the pivotal study could begin in Q4 of 2018/Q1 of 2019, he contends. Additionally, Zhong expects the initial data from the LGMD2E gene therapy program to be positive, based on a readthrough from the micro-dystrophin program. He reiterates a Buy rating and $200 fair value estimate on the shares.
10/04/18
NEED
10/04/18
NO CHANGE
NEED
Needham impressed with Sarepta micro-dystrophin gene therapy data
Needham analyst Chad Messer reiterated a Buy rating and $196 price target after updated data from Sarepta's micro-dystrophin gene therapy program was presented at the World Muscle Society Congress. The data indicated that all four patients showed "impressive improvements on multiple functional measures," and Messer noted that Sarepta has already requested an FDA meeting and expects to initiate a pivotal study by the end of this year.
10/04/18
FBCO
10/04/18
NO CHANGE
Target $189
FBCO
Outperform
Sarepta price target raised to $189 from $178 at Credit Suisse

TODAY'S FREE FLY STORIES

PBF

PBF Energy

$29.29

0.64 (2.23%)

05:39
10/21/19
10/21
05:39
10/21/19
05:39
Upgrade
PBF Energy rating change  »

PBF Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SAP

SAP

$129.13

0.55 (0.43%)

05:38
10/21/19
10/21
05:38
10/21/19
05:38
Earnings
SAP reports Q3 non-IFRS EPS EUR 1.30 vs. EUR 1.14 last year »

Reports Q3 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

DANOY

Danone

$0.00

(0.00%)

05:32
10/21/19
10/21
05:32
10/21/19
05:32
Downgrade
Danone rating change  »

Danone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

JBAXY

Julius Baer

$0.00

(0.00%)

05:30
10/21/19
10/21
05:30
10/21/19
05:30
Downgrade
Julius Baer rating change  »

Julius Baer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHR

Danaher

$138.08

0.31 (0.23%)

05:28
10/21/19
10/21
05:28
10/21/19
05:28
Hot Stocks
Danaher to sell certain businesses to Sartorius AG for $750M »

Danaher announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

SAP

SAP

$129.13

0.55 (0.43%)

, MSFT

Microsoft

$137.34

-2.34 (-1.68%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Hot Stocks
SAP enters go-to-market partnership with Microsoft »

SAP (SAP) and Microsoft…

SAP

SAP

$129.13

0.55 (0.43%)

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

ALSMY

Alstom

$0.00

(0.00%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Downgrade
Alstom rating change  »

Alstom downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$0.00

(0.00%)

05:25
10/21/19
10/21
05:25
10/21/19
05:25
Downgrade
Danone rating change  »

Danone downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HON

Honeywell

$165.61

-1.87 (-1.12%)

05:24
10/21/19
10/21
05:24
10/21/19
05:24
Hot Stocks
Honeywell sees 7,600 new business jet deliveries over next decade »

The business jet industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

05:23
10/21/19
10/21
05:23
10/21/19
05:23
Downgrade
Boeing rating change  »

Boeing downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IRT

Independence Realty Trust

$15.03

(0.00%)

05:22
10/21/19
10/21
05:22
10/21/19
05:22
Downgrade
Independence Realty Trust rating change  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

RHHBY

Roche

$0.00

(0.00%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Hot Stocks
Genentech says Phase III IMbrave150 study met co-primary endpoints »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 12

    Nov

  • 07

    Dec

PINS

Pinterest

$25.30

-0.7 (-2.69%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Upgrade
Pinterest rating change  »

Pinterest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 19

    Nov

COMM

CommScope

$11.56

-0.06 (-0.52%)

05:20
10/21/19
10/21
05:20
10/21/19
05:20
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

  • 09

    Dec

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

05:18
10/21/19
10/21
05:18
10/21/19
05:18
Recommendations
Micro Focus, OpenText analyst commentary  »

Micro Focus could attract…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

, CRM

Salesforce

$144.18

-1.995 (-1.36%)

05:15
10/21/19
10/21
05:15
10/21/19
05:15
Recommendations
Microsoft, Salesforce, Intuit, SailPoint, Zuora, Varonis analyst commentary  »

High growth software…

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

CRM

Salesforce

$144.18

-1.995 (-1.36%)

INTU

Intuit

$262.54

-4.03 (-1.51%)

SAIL

SailPoint

$18.32

-0.34 (-1.82%)

ZUO

Zuora

$13.63

-0.5 (-3.54%)

VRNS

Varonis

$62.36

-1.56 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

  • 16

    Dec

XLRN

Acceleron

$42.16

-1.02 (-2.36%)

05:09
10/21/19
10/21
05:09
10/21/19
05:09
Recommendations
Acceleron analyst commentary  »

Piper sees near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

  • 04

    Apr

TLSNF

Telia

$0.00

(0.00%)

05:04
10/21/19
10/21
05:04
10/21/19
05:04
Downgrade
Telia rating change  »

Telia downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALRM

Alarm.com

$47.23

-0.5 (-1.05%)

05:01
10/21/19
10/21
05:01
10/21/19
05:01
Upgrade
Alarm.com rating change  »

Alarm.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

  • 09

    Dec

SWAV

ShockWave Medical

$32.30

-0.29 (-0.89%)

04:59
10/21/19
10/21
04:59
10/21/19
04:59
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

APLS

Apellis

$27.78

-0.03 (-0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Apellis participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Dec

FPRX

Five Prime

$3.98

-0.11 (-2.69%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Five Prime management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

ADAP

Adaptimmune

$0.96

-0.035 (-3.54%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Adaptimmune management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

ALDR

Alder Biopharmaceuticals

$18.92

0.02 (0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Feb

04:55
10/21/19
10/21
04:55
10/21/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.